This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences 将来の成長

Future 基準チェック /56

主要情報

59.0%

収益成長率

60.27%

EPS成長率

Biotechs 収益成長	23.7%
収益成長率	27.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	10 Mar 2023

今後の成長に関する最新情報

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18

業績と収益の成長予測

NYSE:MYOV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2025	618	-74	N/A	N/A	2
3/31/2024	555	-76	N/A	N/A	3
3/31/2023	418	-153	N/A	N/A	2
12/31/2022	379	-184	-271	-270	N/A
9/30/2022	333	-190	-260	-259	N/A
6/30/2022	306	-166	-232	-231	N/A
3/31/2022	231	-206	-270	-269	N/A
12/31/2021	198	-228	-263	-261	N/A
9/30/2021	145	-238	403	405	N/A
6/30/2021	67	-284	318	319	N/A
3/31/2021	59	-255	369	371	N/A
12/31/2020	35	-239	443	444	N/A
9/30/2020	33	-250	-198	-197	N/A
6/30/2020	33	-254	-217	-216	N/A
3/31/2020	N/A	-289	-222	-221	N/A
12/31/2019	N/A	-299	-256	-255	N/A
9/30/2019	N/A	-284	-252	-250	N/A
6/30/2019	N/A	-279	-247	-246	N/A
3/31/2019	N/A	-274	-225	-224	N/A
12/31/2018	N/A	-247	-207	-206	N/A
9/30/2018	N/A	-218	-176	-175	N/A
6/30/2018	N/A	-182	-136	-135	N/A
3/31/2018	N/A	-143	-118	-117	N/A
12/31/2017	N/A	-117	-94	-93	N/A
9/30/2017	N/A	-83	-70	-69	N/A
6/30/2017	N/A	-88	-46	-45	N/A
3/31/2017	N/A	-83	-19	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MYOVは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.1% ) よりも高い成長率であると考えられます。

収益対市場: MYOV今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: MYOV今後 3 年以内に収益を上げることが予想されます。

収益対市場: MYOVの収益 ( 27.6% ) US市場 ( 10.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: MYOVの収益 ( 27.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MYOVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2023/03/12 21:46
終値	2023/03/09 00:00
収益	2022/12/31
年間収益	2022/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Myovant Sciences Ltd. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。8

アナリスト	機関
Brian Skorney	Baird
Mohit Bansal	Citigroup Inc
Jason Butler	Citizens JMP Securities, LLC

This company has been acquired

Myovant Sciences 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased to US$20.40

Consensus EPS estimates fall by 29%

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Consensus forecasts updated

Price target decreased to US$22.80

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Principal Financial Officer recently sold US$174k worth of stock

Women Can Thank Pfizer And Myovant For MYFEMBREE

Myovant Sciences: Regulatory Overhang Cleared

General Counsel & Corporate Secretary recently sold US$569k worth of stock

Price target increased to US$20.40

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Myovant stock gains ~6% after hours on Q1 revenue jump

CEO & Director recently sold US$144k worth of stock

Consensus EPS estimates fall by 29%

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Price target decreased to US$22.80

Less than half of directors are independent

Myovant: Poised To Overcome Regulatory Issues

General Counsel & Corporate Secretary recently sold US$84k worth of stock

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Price target decreased to US$24.80

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold US$292k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold US$73k worth of stock

Myovant: Catalysts Powering More Upside

Chief Medical Officer exercised options and sold US$62k worth of stock

Price target decreased to US$28.40

General Counsel & Corporate Secretary recently sold US$144k worth of stock

Chief Medical Officer exercised options and sold US$116k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Price target decreased to US$33.25

Chief Medical Officer exercised options and sold US$342k worth of stock

Less than half of directors are independent

Key Executive recently sold US$70k worth of stock

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Consensus forecasts updated

General Counsel & Corporate Secretary recently sold US$202k worth of stock

General Counsel & Corporate Secretary notifies of intention to sell stock

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Analysts update estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Revenue and earnings miss expectations

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Analysts increase revenue estimates to US$42.9m

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Myovant Sciences Ltd Appoints David Marek as Principal Executive Officer and Member of the Board of Directors

Key Executive notifies of intention to sell stock

Myovant Sciences Ltd. and Pfizer Inc. Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’S Health